Skip to main content
Sign In

Behbakht Lab

Behbakht (Resized) 2.jpg

The Behbakht lab focuses on clinical, translational, and basic science approaches to finding novel treatments for ovarian cancer.  We have recently adopted an ex-vivo technique to slice fresh ovarian tumor samples, investigating the effectiveness of anti-cancer treatments in a system that maintains the tumor in its native stromal microenvironment.   ​

​Lab Personnel​

Lubna Qamar: Lab Manager

Annette Joglar: Tissue Bank Coordinator

Crystal Adams: WRHR Fellow

Chris Breed: Gynecologic Oncology Fellow

Greg Futia: Graduate student


Dr. Heide Ford: Department of Pharmacology

Dr. Andrew Thorburn: Department of Pharmacology

Dr. Emily Gibson: Department of Bioengineering

Dr. Heidi Wilson: Department of Obstetrics & Gynecology

2013          University of Colorado Extraordinary Service Award​​

2009          Resident Teaching Award - University of Colorado Denver

2003-07     NCI K-12 Clinical Oncology Scholars Award

2002          Cook County Hospital Excellence in Teaching Award

1995          American Society of Clinical Oncology Young Investigator Award

1994          Fellow Research Award - Rush Medical College

1993          Resident Surgical Skills Award - Rush Medical College

1991          Galloway Fellow in Gynecologic Oncology - Memorial-Sloan-Kettering Cancer Center

Cytokeratin 5 positive cells represent a therapy resistant subpopulation in epithelial ovarian cancer. Bradley R. Corr, Jessica Finlay-Schultz, Rachel B. Rosen, Lubna Qamar, Miriam D. Post, Kian Behbakht, Monique A. Spillman, and Carol A. Sartorius (submitted).

Progestin Treatment Decreases CD133+ Cancer Stem Cell Populations in Endometrial Cancer. Michael Stephen Guy, MD; Lubna Qamar, PhD; Kian Behbakht, MD; Miriam Post, MD; Jeanelle Sheeder, MSPH, PhD; Carol Sartorius, PhD; Monique Spillman, PhD (submitted)

Awareness of symptoms and risk factors of ovarian cancer in a population of women and healthcare providers. Goldstein CL, Susman E, Lockwood S, Medlin EE, Behbakht K. Clin J Oncol Nurs. 2015 Apr;19(2):206-12. doi: 10.1188/15.CJON.206-212.

Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. J Clin Oncol. 2015 Apr 1;33(10):1180-5. doi: 10.1200/JCO.2014.58.3781. Epub 2015 Feb 23.

Association between gelatin-thrombin matrix use and abscesses in women undergoing pelvic surgery. Anderson CK, Medlin E, Ferriss AF, Sheeder J, Davidson S, Gibbs R, Behbakht K, Guntupalli SR. Obstet Gynecol. 2014 Sep;124(3):589-95. doi: 10.1097/AOG.0000000000000406.

Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. Kim Y, Guntupalli SR, Lee SJ, Behbakht K, Theodorescu D, Lee JK, Diamond JR. PLoS One. 2014 Feb 5;9(2):e86532. doi: 10.1371/journal.pone.0086532. eCollection 2014.

Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer.  Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K. Gynecol Oncol. 2012 May;125(2):451-7. doi: 10.1016/j.ygyno.2012.02.007. Epub 2012 Feb 12.

Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, Kelly MG. Int J Gynecol Cancer. 2011 Nov;21(8):1422-7. doi: 10.1097/IGC.0b013e31822c7704.

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12.

Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model. Qamar L, Davis R, Anwar A, Behbakht K. Gynecol Oncol. 2008 Sep;110(3):425-31. doi: 10.1016/j.ygyno.2008.04.039. Epub 2008 Jul 10.

Bristol-Myers Squibb (Guntupalli/Behbakht)

"The Safety of Oral Apixaban (Eliquis) versus Subcutaneous Enoxaparin (Lovenox) for Thromboprophylaxis in Women with Suspected Pelvic Malignancy; a Prospective Randomized Open Blinded End-point (PROBE) Design.” 

Bioscience Discovery and Evaluation Grant (Neville/Wilson/Behbakht)

State of Colorado & University of Colorado Technology Transfer Office

“Toxicity Studies on a peptide targeting claudins in tumor cells”

W81XWH-14-1-0170 (Ford/Zhao/Behbakht)

The Department of Defense (DOD) Ovarian Cancer Idea Award

“Targeting the Six1/Eya Transcriptional Complex for Ovarian Cancer Therapy